CAR-T therapy has revolutionized hematologic oncology, yet it comes with side effects. 𝘊𝘺𝘵𝘰𝘬𝘪𝘯𝘦 𝘙𝘦𝘭𝘦𝘢𝘴𝘦 𝘚𝘺𝘯𝘥𝘳𝘰𝘮𝘦 (𝘊𝘙𝘚) and 𝘪𝘮𝘮𝘶𝘯𝘦 𝘦𝘧𝘧𝘦𝘤𝘵𝘰𝘳 𝘤𝘦𝘭𝘭-𝘢𝘴𝘴𝘰𝘤𝘪𝘢𝘵𝘦𝘥 𝘯𝘦𝘶𝘳𝘰𝘵𝘰𝘹𝘪𝘤𝘪𝘵𝘺 𝘴𝘺𝘯𝘥𝘳𝘰𝘮𝘦 (𝘐𝘊𝘈𝘕𝘚) are the most significant toxicities. CRS can occur in 50–90% of patients, while ICANS is reported in 20–50% of cases [1,2]. 

𝗖𝗥𝗦 manifests as fever, hypotension, hypoxia, and multi-organ involvement due to massive cytokine release. 𝗡𝗲𝘂𝗿𝗼𝘁𝗼𝘅𝗶𝗰𝗶𝘁𝘆 ranges from confusion, tremor, aphasia, to seizures. Both require careful monitoring, early intervention with tocilizumab or corticosteroids, and clinical expertise. 

𝗘𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗖𝗔𝗥-𝗧 𝗱𝗲𝘀𝗶𝗴𝗻𝘀 aim to mitigate these risks. 𝘜𝘯𝘪𝘊𝘈𝘙, for instance, uses 𝘮𝘰𝘥𝘶𝘭𝘢𝘳 𝘊𝘈𝘙𝘴 𝘸𝘪𝘵𝘩 𝘢 𝘴𝘸𝘪𝘵𝘤𝘩𝘢𝘣𝘭𝘦 𝘢𝘥𝘢𝘱𝘵𝘦𝘳, allowing therapy to be paused or modulated to control cytokine surge [3]. 𝘚𝘰𝘭𝘪𝘥 𝘵𝘶𝘮𝘰𝘳 𝘊𝘈𝘙-𝘛𝘴 face additional hurdles, including antigen heterogeneity, immunosuppressive tumor microenvironments (TME), and poor infiltration, where CRS may still occur but tumor killing is limited [4]. 

𝗢𝘁𝗵𝗲𝗿 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 include 𝘕𝘒-𝘊𝘈𝘙 𝘵𝘩𝘦𝘳𝘢𝘱𝘪𝘦𝘴, which tend to induce lower cytokine peaks, and TCR-engineered therapies, which may reduce severe CRS while targeting intracellular antigens [5]. 

𝗦𝗽𝗲𝗰𝘂𝗹𝗮𝘁𝗶𝘃𝗲 𝗵𝘆𝗽𝗼𝘁𝗵𝗲𝘀𝗶𝘀: Designing CAR-T cells with tunable activation, synthetic ´on/off´ safety switches, or graded co-stimulatory domains could allow for adaptive modulation of cytokine secretion. Coupling this with TME-responsive CARs that only fully activate in the presence of tumor-specific signals could minimize systemic toxicity while maintaining potent anti-tumor activity. Combining this approach with localized cytokine blockers (small inhibitors) or short-lived cytokine decoy receptors could further prevent CRS and neurotoxicity without impairing efficacy. 

𝗔𝘂𝗱𝗶𝗲𝗻𝗰𝗲 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻: How would you engineer a CAR-T or NK-CAR system to maximize tumor killing in a hostile TME while minimizing CRS and neurotoxicity? 

Stay tuned for 𝗗𝗮𝘆 𝟱𝟳: 𝗖𝗔𝗥-𝗧 𝗶𝗻 𝗦𝗼𝗹𝗶𝗱 𝗧𝘂𝗺𝗼𝗿𝘀 – 𝗢𝘃𝗲𝗿𝗰𝗼𝗺𝗶𝗻𝗴 𝘁𝗵𝗲 𝗧𝗠𝗘 

𝗥𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲𝘀: 
1. DOI: 10.1182/blood-2014-05-552729 
2. DOI: 10.1056/NEJMoa1707447 
3. DOI: 10.4049/jimmunol.1801004 
4. DOI: 10.1038/s41571023-00754-1 
5. DOI: 10.1038/s41420-024-02077-1 

#CAR_T #Immunotherapy #CancerImmunology #CRS #Neurotoxicity #AdoptiveCellTherapy #UniCAR #NK_CAR #TCR_Therapy #TumorMicroenvironment #CytokineManagement #CellTherapy #OncologyResearch #TranslationalResearch #PrecisionMedicine